Glow Lifetech Corp. (GLWLF)
USD 0.04
(-10.06%)
USD 0.04
(-10.06%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.71 Thousand CAD | -33.64% |
| 2022 | 1.25 Million USD | -69.57% |
| 2021 | 4.13 Million USD | 3335.03% |
| 2020 | 120.47 Thousand USD | -14.53% |
| 2019 | 140.94 Thousand USD | 0.44% |
| 2018 | 140.32 Thousand USD | -61.62% |
| 2017 | 365.63 Thousand USD | 224.77% |
| 2016 | 112.58 Thousand USD | -11.2% |
| 2015 | 126.78 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 209.72 Thousand USD | -6.12% |
| 2024 Q2 | 198.47 Thousand USD | 7.03% |
| 2023 FY | 835.78 Thousand USD | -33.64% |
| 2023 Q4 | 228.33 Thousand USD | 10.68% |
| 2023 Q3 | 206.31 Thousand USD | -17.26% |
| 2023 Q2 | 249.35 Thousand USD | 33.55% |
| 2023 Q1 | 186.71 Thousand USD | -29.34% |
| 2022 Q4 | 264.23 Thousand USD | 38.8% |
| 2022 FY | 1.25 Million USD | -69.57% |
| 2022 Q3 | 190.37 Thousand USD | -49.07% |
| 2022 Q2 | 373.81 Thousand CAD | -22.57% |
| 2022 Q1 | 482.8 Thousand CAD | -19.1% |
| 2021 Q1 | 2.49 Million CAD | 25150.44% |
| 2021 Q4 | 596.81 Thousand CAD | 65.35% |
| 2021 FY | 4.13 Million USD | 3335.03% |
| 2021 Q3 | 360.94 Thousand CAD | -61.74% |
| 2021 Q2 | 943.47 Thousand CAD | -62.18% |
| 2020 Q4 | -9958.00 CAD | -101.44% |
| 2020 FY | 120.47 Thousand USD | -14.53% |
| 2020 Q3 | 691.52 Thousand CAD | 1679.42% |
| 2020 Q2 | 38.86 Thousand CAD | -1.13% |
| 2020 Q1 | 39.3 Thousand CAD | -20.82% |
| 2019 Q1 | 21.58 Thousand CAD | 0.0% |
| 2019 FY | 140.94 Thousand USD | 0.44% |
| 2019 Q4 | 49.63 Thousand CAD | 40.29% |
| 2019 Q3 | 35.38 Thousand CAD | -53.55% |
| 2019 Q2 | 76.16 Thousand CAD | 252.87% |
| 2018 FY | 140.32 Thousand USD | -61.62% |
| 2017 FY | 365.63 Thousand USD | 224.77% |
| 2016 FY | 112.58 Thousand USD | -11.2% |
| 2015 FY | 126.78 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.97% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 99.477% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.97% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.913% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.931% |
| Mesoblast Limited | 5.9 Million USD | 99.564% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 98.288% |
| Genus plc | 147.7 Million USD | 99.983% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.707% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 98.083% |
| Marizyme, Inc. | 19.23 Million USD | 99.866% |
| ContraFect Corporation | 56.88 Million USD | 99.955% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.692% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 99.417% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 98.261% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 99.118% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 99.078% |
| MultiCell Technologies, Inc. | 567.42 USD | -4431.916% |
| Accustem Sciences Inc. | 3.74 Million USD | 99.314% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.97% |
| EV Biologics, Inc. | 531.96 Thousand USD | 95.166% |
| Q BioMed Inc. | 3.43 Million USD | 99.252% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.896% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 93.399% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 99.021% |
| Biomind Labs Inc. | 994.18 Thousand USD | 97.413% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.989% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.617% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.81% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 98.745% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 202.86% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 99.49% |
| IMV Inc. | 37.7 Million USD | 99.932% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.839% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 98.599% |
| GB Sciences, Inc. | 1.42 Million USD | 98.19% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.735% |
| HST Global, Inc. | 140.9 Thousand USD | 81.75% |
| CSL Limited | 3.44 Billion USD | 99.999% |
| Halberd Corporation | 74.84 Thousand USD | 65.641% |
| Enzolytics Inc. | 2.17 Million USD | 98.82% |
| Resverlogix Corp. | 12.71 Million USD | 99.798% |
| Affymax, Inc. | 39.38 Million USD | 99.935% |
| SYBLEU INC | 160.87 Thousand USD | 84.016% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 99.296% |
| argenx SE | 1.53 Billion USD | 99.998% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.955% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 97.537% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 98.372% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 99.245% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.648% |
| Zenith Capital Corp. | 8.94 Million USD | 99.712% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.997% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -47.609% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 98.953% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 85.007% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.974% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 98.539% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 98.696% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 98.621% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.763% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 98.661% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.888% |
| ONE Bio Corp. | 6.44 Million USD | 99.601% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 85.831% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 98.074% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 97.714% |
| Agentix Corp. | 1.37 Million USD | 98.125% |
| LadRx Corporation | 3.81 Million USD | 99.325% |
| Cell Source, Inc. | 4.32 Million USD | 99.405% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 93.811% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.216% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.216% |
| NovAccess Global Inc. | 2.46 Million USD | 98.958% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 98.931% |
| Itoco Inc. | 919.14 Thousand USD | 97.202% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 99.393% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 97.702% |
| Kadimastem Ltd | 2.41 Million USD | 98.933% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 90.175% |
| CytoDyn Inc. | 18.05 Million USD | 99.858% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -2.169% |
| Mobile Lads Corp. | 554.54 Thousand USD | 95.363% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 88.316% |
| Qrons Inc. | 643.67 Thousand USD | 96.005% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 98.189% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 98.847% |
| Rebus Holdings, Inc. | 664 Thousand USD | 96.127% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 98.584% |
| International Stem Cell Corporation | 5.27 Million USD | 99.512% |
| Bioxytran, Inc. | 3.82 Million USD | 99.327% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 51.151% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -26.407% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.929% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 98.411% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 96.505% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 99.173% |
| Neutra Corp. | 243.82 Thousand USD | 89.453% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.853% |
| PureTech Health plc | 144.59 Million USD | 99.982% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.874% |
| IXICO plc | 4.7 Million USD | 99.454% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.708% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.978% |
| CSL Limited | 3.89 Billion USD | 99.999% |
| Cellectis S.A. | 97.32 Million USD | 99.974% |